A maker of mission-critical materials for labs and biopharma, Avantor sells high-purity chemicals (J.T. Baker), tubing (Masterflex), and medical-grade silicones (NuSil), delivered worldwide through its VWR channel. Its roots trace to 1904, when chemist John Townsend Baker began producing purer lab reagents; NuSil and the 1852-founded VWR distributor later joined the fold. Fun fact: in a 1993 silicone shortage, NuSil cloned discontinued materials so device makers could keep producing long-term implants.
VWR Distribution goodwill remains at risk after Q2 revenue rose 0.5% but gross margin fell 1.2 points
VWR Distribution stays at risk of a material non-cash charge. Q2 rose 0.5% to $1,692.3M while contracted 1.2 points to 31.7% on mix, inflation, and lower volumes, and dropped 41% to $38.1M. The company faces a possible that could hit earnings without warning.
Key takeaways
The VWR Distribution reporting unit's fair value exceeded carrying value by only ~5.5% as of Q1 2026, and this 10-Q adds a risk factor warning of a material non-cash if operating performance or cash-flow forecasts deteriorate.
Consolidated increased 0.5% to $1,692.3M, driven by VWR Distribution & Services growth, while declined 0.4%.
contracted 120 to 31.7% due to unfavorable product mix, inflationary pressures, and lower sales volumes.
Section summaries
Management's Discussion and Analysis
Q2 FY2026 net sales rose 0.5% to $1.69B but margins contracted on mix, inflation, and lower volumes; VWR Distribution goodwill remains at risk.
⌄
Consolidated increased 0.5% to $1,692.3M, driven by VWR Distribution & Services growth, while organic sales declined 0.4%.
fell 10.7% to $225.1M, with Bioscience & Medtech down 10.5% and VWR Distribution down 10.7%.
dropped 41% to $38.1M, pressured by lower and a higher , partly offset by reduced .
decreased $39.5M to $168.0M for the six months on lower and higher .
What changed
Q1 2026 flagged the VWR Distribution unit's ~5.5% fair-value cushion and risk after a share-price decline; Q2 confirms the risk with a new dedicated risk factor and no charge recorded.
Q1 2026 tracked against a 4.1% decline; Q2 organic sales came in at -0.4%, a reversal toward flatter performance.
Q1 2026 watch on Q2 against $58.7M: the six-month was $168.0M, down $39.5M from a year earlier, continuing the cash decline.
FY2025 watch on from $3,915.5M: Q2 2026 long-term debt was $3,779.3M, down 3.5% quarter over quarter.
The Q1 2026 interim test showed no charge; Q2 reaffirms the unit remains at risk with the same ~5.5% margin disclosed.
What to watch
Track Q3 2026 against the -0.4% Q2 level for a turn to positive growth.
Monitor the VWR Distribution reporting unit for a charge if share price or cash-flow forecasts deteriorate.
Follow Q3 against the $168.0M six-month print as and shift.
Watch from $3,779.3M against variable-rate exposure as rates stay elevated.
contracted 120 to 31.7% due to unfavorable product mix, inflationary pressures, and lower sales volumes.
fell 10.7% to $225.1M, with declines in both segments: Bioscience & Medtech down 10.5% and VWR Distribution down 10.7%.
dropped 41% to $38.1M, pressured by lower and a higher , partially offset by reduced .
decreased $39.5M to $168.0M for the six months, reflecting lower and higher .
The VWR Distribution reporting unit's fair value exceeded its carrying value by only ~5.5% as of Q1 2026, signaling continued risk of a material .
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and qualitative disclosures about market risk appear in Item 7A “Quantitative and qualitative disclosures about market risk” in our Annual Report. There were no material changes during the quarter ended June 30, 2026 to this information as reported in our Annual Rep…
⌄
Quantitative and qualitative disclosures about market risk appear in Item 7A “Quantitative and qualitative disclosures about market risk” in our Annual Report. There were no material changes during the quarter ended June 30, 2026 to this information as reported in our Annual Report.
For additional information regarding legal proceedings and matters, see note 8 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements,” in this report, which information is incorporated into this item by reference.
⌄
For additional information regarding legal proceedings and matters, see note 8 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements,” in this report, which information is incorporated into this item by reference.
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report and the following risk factor, which supplements and should be read i…
⌄
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report and the following risk factor, which supplements and should be read in conjunction with the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report.
Our VWR Distribution reporting unit is at risk of goodwill impairment, which could result in a material non‑cash charge.
Our consolidated balance sheet includes goodwill, intangible assets and other long-lived assets that must be periodically evaluated for potential impairment. We assess the realizability of the reported goodwill, intangible assets and other long-lived assets annually, as well as whenever events or changes in circumstances indicate that the assets may be impaired. During the first quarter of 2026, a sustained decline in our share price and market capitalization constituted a triggering event that required an interim goodwill impairment assessment. Although no impairment was recorded, the VWR Distribution reporting unit is considered at risk of impairment because the estimated fair value exceeded the carrying value by a limited margin. The valuation is sensitive to adverse changes in operating performance, forecasted cash flows, discount rates and market conditions. If these factors deteriorate, we could be required to record a material non‑cash goodwill impairment charge in a future reporting period (see note 7 to the unaudited condensed consolidated financial statements included in this quarterly report).